Articles On Orthocell (ASX:OCC)

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Orthocell’s sales ramped up in three months to June with the Perth-based regenerative medicine company described as testament to the quality of its products and distribution partners.

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Australian regenerative medicine company Orthocell (ASX:OCC) has appointed John Van Der Wielen as independent non-executive chairman.

Orthocell has launched a new bio-manufacturing facility in what boss Paul Anderson said represented the successful translation of quality science into a world-class product.

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The Australian share market dipped on Tuesday, with the benchmark ASX 200 index down nearly 20 points halfway through the trading day. The materials sector led the pack in early trade — the only sector to edge into the green. Critical...

Neuren’s breakthrough drug DAYBUE starts selling in the US Orthocell commences nerve repair study   Market darling Neuren Pharma (ASX:NEU) jumped 4% today after announcing that DAYBUE (trofinetide) is now officially available for the trea...

Orthocell (OCC) kicks off a ‘comparator’ study as part of its pre-clinical and clinical development program in nerve repair and regeneration OCC will use a rat sciatic nerve injury model to evaluate the safety, mechanism of action and pr...

Labor has announced that if elected it will launch a $38 million expansion of Australia's newborn screening programs in a move that will effectively see the national take over the current 'postcode lottery' for babies.

Orthocell (OCC) appoints internationally-recognised nerve surgeons Professor Christopher Dy and Professor David Brogan to its medical scientific advisory board The company says the appointments will assist with clinical development and U...

Telehealth specialist Global Health signs partnership deal with Woolworths subsidiary The deal will see Global Health provide virtual access to healthcare practitioners Orthocell hires experts to drive US market entry   Telehealth special...

Orthocell says a $23 million manufacturing deal for its product has put the regenerative medicine company on the radar of global industry heavyweights, paving the way for other WA firms to do the same.

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Surgeons can now be reimbursed for the use of Orthocell’s nerve-reconstruction device SaaS player ReadyTech is considering a takeover offer from an Aussie private equity firm Creso is raising up to $7.6m to advance sales and marketing of i...

Orthocell’s (OCC) Remplir product is included on the Australian Prostheses ListThe company says inclusion in the list enables surgeons to receive reimbursement from private insurers for the use of Remplir in peripheral nerve repair procedur...

Regenerative medicine company Orthocell (ASX:OCC) has announced that its Remplir has been added to the federal government's Prostheses List.

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

ShareCafeRebound rally: Aus shares close 1.4 per cent higher by Lauren Hayes   The S&P/ASX 200 enjoyed a rebound today, with the market up 2 per cent in intraday trading, closing 1.44 per cent or 93 points higher at 6555.00. All 11 sect...

Orthocell (OCC) reports positive results from its crossover patient extension arm of its rotator cuff tendon clinical studyThe results demonstrated OrthoATI is a safe and effective treatment for patients suffering from rotator cuff tendinop...

ShareCafeResurgent ASX rallies: Aus shares 1.8% higher at noon By Lauren Hayes   At noon, the S&P/ASX 200 is 1.82 per cent or 117.70 points higher at 6579.70. The SPI futures are pointing to a rise of 116 points. Inflation data out toda...

Nasdaq-listed Biogen says its experimental Alzheimer’s drug study was successful The news sends ASX-listed Cogstate to soar Orthocell could have the first FDA-approved injectable cell therapy in orthopaedics  Big news out of Nasdaq-listed...

The ASX will open much higher on Thursday Wall Street rallied strongly overnight as yields slump following BoE’s decision The BoE has surprised the market with bond buyback announcement Local shares are set to open much higher on Thursday...

PYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical programs Orthocell gets first purchase orders The race is hotting up to develop the next RNA-based drug discovery, as a couple of ASX liste...

Orthocell (OCC) receives its first purchase orders for its Striate+ and Remplir products from partners BioHorizons and DVT, respectivelyStriate+ is used in guided bone and tissue regeneration procedures, and Remplir is a collagen nerve wrap...

Orthocell (OCC) appoints an exclusive Australian distributor for RemplirThe company penned a distributor agreement with Device Technologies, making the company its exclusive distributor for its peripheral nerve repair treatmentDevice Techno...

Perth-based regenerative medicine company Orthocell has inked a new deal with Device Technologies to distribute its nerve repair device in a bid to commercialise the technology across Australia and New Zealand.

ASX 200 drops load circa 1430 (AEST)  ends 0.4% lower Small caps index laughs openly in face of danger, gains 1% RBA hits us with another 50bps rate hike   The ASX 200 — not unlike the still, glassy ocean before a hurricane — was flat an...

DR BOREHAM’S CRUCIBLE: ORTHOCELL Market cap: $74.9m Shares on issue: 197,127,913 Chief executive officer: Paul Anderson Board: Dr Stewart Washer (chair), Mr Anderson, Matthew Callahan, Prof Lars Lidgren, Qi Xiao Zhou, Leslie Wise Finances (...

ShareCafeEvening Report: 21 July, 2022 by Paul Sanger   At the closing bell, the S&P/ASX 200 was 0.52 per cent or 35.10 points higher at 6794.30. The lithium and green metals sector was on fire today, after electric vehicle maker Tesla...

Orthocell (OCC) takes the next steps in its license and distribution agreements for its Striate+ dental membrane for bone regeneration   The exclusive patent and trademark licence agreement and distribution agreement is with Delaware corpo...

ShareCafeLunch Report: 21 July, 2022 by Paul Sanger   Australian shares are little changed in mixed trading this morning. At noon, the S&P/ASX 200 is 0.05 per cent or 3.60 points lower at 6755.60. Australian lithium and nickel companies...

ShareCafeStocks of the Hour: 21 July, 2022                  Orthocell (ASX:OCC) recently signed a global exclusive licence and distribution agreement with BioHorizons Implant Systems Inc, one of the largest dental implant companies in...

21 Jul 2022 - A snapshot of the stocks on the move featuring Orthocell (ASX:OCC), Telix Pharmaceuticals (ASX:TLX) and Asra Minerals (ASX:ASR).

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

ShareCafeOrthocell (ASX: OCC) – Webinar presentation Paul Anderson – Managing DIrector – Orthocell is a world-leading regenerative medicine company providing innovative products to restore mobility, function and performance. More Orthocell...

ShareCafeWebinar Recap – PCK, OCC, LCL & ICE Catch up on the full webinar presentations from PainChek (ASX: PCK), Orthocell (ASX: OCC), Los Cerros (ASX: LCL) & icetana (ASX: ICE) Webinar Recap – PCK, OCC, LCL & ICEStaff Writers

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

The ASX200 makes it four gains in a row The small cap index remains uninspired despite some strong individual performances HRL and 4DX deliver huge returns on Tuesday   The benchmark XJO is up by 0.6%. The little XEC index is not. The ASX...

Shares in regenerative medicine company Orthocell are flying after it signed a licencing and manufacturing deal worth $23.1 million with one of the world’s largest dental implant companies. 

Orthocell jumps 35% after signing global license deal Imricor in with Siemens deal on 3D imaging system CardieX submits “Pulse” application with US FDA  Orthocell (ASX:OCC) jumped by over 35% this morning after signing a 25-year exclusive...